© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Implications for assessing MRD status in patients with transplant-ineligible myeloma and treating appropriate patients with the combination of daratumumab, lenalidomide, and dexamethasone.
December 23rd 2020
Mayo Clinic’s Rafael Fonseca, MD, comments on the benefits of newer therapies that are now available for patients with newly diagnosed transplant-ineligible multiple myeloma.
Considerations for adding daratumumab to the combination of lenalidomide and dexamethasone to treat transplant-ineligible newly diagnosed multiple myeloma based on updated efficacy data from the phase 3 MAIA trial.
Insight regarding the assessment of minimal residual disease in patients with multiple myeloma and using testing results to aid in treatment selection.
Hematologist Rafael Fonseca comments on data demonstrated by the PEGASUS study in transplant-ineligible multiple myeloma and expectations for treating appropriate patients with the combination of daratumumab, lenalidomide, and dexamethasone vs other options moving forward.
Considerations regarding current clinical practice patterns for transplant-ineligible myeloma and the uptake of newer data by health care professionals.